WO2023227781 - A PHARMACEUTICAL FORMULATION FOR PRESSURISED METERED DOSE INHALER
National phase entry:
Publication Number
WO/2023/227781
Publication Date
30.11.2023
International Application No.
PCT/EP2023/064258
International Filing Date
26.05.2023
Title **
[English]
A PHARMACEUTICAL FORMULATION FOR PRESSURISED METERED DOSE INHALER
[French]
FORMULATION PHARMACEUTIQUE POUR AÉROSOL-DOSEUR SOUS PRESSION
Applicants **
CHIESI FARMACEUTICI S.P.A.
Inventors
ZAMBELLI, Enrico
BONELLI, Sauro
MATTURRO, Angelo Benedetto
USBERTI, Francesca
CAVECCHI, Alessandro
Priority Data
22175770.1
27.05.2022
EP
Application details
| Total Number of Claims/PCT | * |
| Number of Independent Claims | * |
| Number of Priorities | * |
| Number of Multi-Dependent Claims | * |
| Number of Drawings | * |
| Pages for Publication | * |
| Number of Pages with Drawings | * |
| Pages of Specification | * |
| * | |
| Number of Office Actions | * |
| * | |
International Searching Authority |
EPO
* |
| Recordal of a Change of the Applicant's Name/Address |
Change of Applicant's Name and Address
* |
| Type of Assignment |
The Standard Agent's Assignment
* |
| Applicant's Legal Status |
Legal Entity
* |
| * | |
| * | |
| * | |
| * | |
| * | |
| Entry into National Phase under |
Chapter I
* |
| Patent Delivery |
Send the Letters Patent by Courier
* |
| 译文 |
|
* The data is based on automatic recognition. Please verify and amend if necessary.
** IP-Coster compiles data from publicly available sources. If this data includes your personal information, you can contact us to request its removal.
Quotation for National Phase entry
| Country | Stages | Total | |
|---|---|---|---|
| China | Filing, Examination, Granting | 2805 | |
| EPO | Filing, Examination, Granting | 21923 | |
| Japan | Filing, Examination, Granting | 2988 | |
| South Korea | Filing, Examination, Granting | 3769 | |
| USA | Filing, Examination, Granting | 9740 |
Total:
41,225
The term for entry into the National Phase has expired. This quotation is for informational purposes only
Contact Us
Abstract[English]
The present invention generally relates to pharmaceutical composition comprising a LABA agent, a LAMA agent, optionally in combination with other active ingredients, a mixture of an acid and a chelating agent, a propellant and a co-solvent. The invention also provides a pharmaceutical composition for the treatment of respiratory diseases, such as asthma and COPD.[French]
La présente invention concerne de manière générale une composition pharmaceutique comprenant un agent LABA, un agent LAMA, éventuellement en combinaison avec d'autres principes actifs, un mélange d'un acide et d'un agent chélatant, un propulseur et un co-solvant. L'invention concerne également une composition pharmaceutique pour le traitement de maladies respiratoires, telles que l'asthme et la BPCO.